Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,834 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S. Matsuo H, et al. Among authors: tanaka s. Haematologica. 2014 Nov;99(11):e225-7. doi: 10.3324/haematol.2014.107128. Epub 2014 Jul 11. Haematologica. 2014. PMID: 25015941 Free PMC article. No abstract available.
Prognostic significance of aminopeptidase-N (CD13) in hepatoblastoma.
Saida S, Watanabe K, Kato I, Fujino H, Umeda K, Okamoto S, Uemoto S, Hishiki T, Yoshida H, Tanaka S, Adachi S, Niwa A, Nakahata T, Heike T. Saida S, et al. Among authors: tanaka s. Pediatr Int. 2015 Aug;57(4):558-66. doi: 10.1111/ped.12597. Epub 2015 Jul 14. Pediatr Int. 2015. PMID: 25682862
CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H, Nakamura N, Tomizawa D, Saito AM, Kiyokawa N, Horibe K, Nishinaka-Arai Y, Tokumasu M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S. Matsuo H, et al. Among authors: tanaka s. Pediatr Blood Cancer. 2016 Aug;63(8):1394-9. doi: 10.1002/pbc.26035. Epub 2016 May 2. Pediatr Blood Cancer. 2016. PMID: 27135782
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Moritake H, Tanaka S, Nakayama H, Miyamura T, Iwamoto S, Shimada A, Terui K, Saito A, Shiba N, Hayashi Y, Tomizawa D, Taga T, Goto H, Hasegawa D, Horibe K, Mizutani S, Adachi S. Moritake H, et al. Among authors: tanaka s. Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26491. Epub 2017 Feb 24. Pediatr Blood Cancer. 2017. PMID: 28233452 No abstract available.
Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia.
Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, Taga T, Fukuda T, Goto H, Inagaki J, Koh K, Ohashi K, Ozawa Y, Inoue M, Kato K, Tanaka J, Atsuta Y, Adachi S, Ishida H. Tomizawa D, et al. Among authors: tanaka j, tanaka s. Biol Blood Marrow Transplant. 2017 Sep;23(9):1515-1522. doi: 10.1016/j.bbmt.2017.05.009. Epub 2017 May 10. Biol Blood Marrow Transplant. 2017. PMID: 28501543 Free article.
Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H, Tomizawa D, Tanaka S, Iwamoto S, Shimada A, Saito AM, Yamashita Y, Moritake H, Terui K, Taga T, Matsuo H, Kosaka Y, Koh K, Hosoi H, Kurosawa H, Isoyama K, Horibe K, Mizutani S, Adachi S. Nakayama H, et al. Among authors: tanaka s. Pediatr Int. 2017 Oct;59(10):1046-1052. doi: 10.1111/ped.13378. Pediatr Int. 2017. PMID: 28771903 Clinical Trial.
Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S, Watanabe T, Taga T, Iwamoto S, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Saito AM, Kiyokawa N, Horibe K, Hara Y, Oki K, Hayashi Y, Tanaka S, Adachi S. Shimada A, et al. Among authors: tanaka s. Int J Hematol. 2018 May;107(5):586-595. doi: 10.1007/s12185-017-2395-x. Epub 2018 Jan 12. Int J Hematol. 2018. PMID: 29330746
Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II-III Randomized Trial (JPLSG AML-12).
Tomizawa D, Tanaka S, Hasegawa D, Iwamoto S, Hiramatsu H, Kiyokawa N, Miyachi H, Horibe K, Saito AM, Taga T, Adachi S. Tomizawa D, et al. Among authors: tanaka s. Jpn J Clin Oncol. 2018 Jun 1;48(6):587-593. doi: 10.1093/jjco/hyy061. Jpn J Clin Oncol. 2018. PMID: 29889285 Clinical Trial.
Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Miyamura T, Moritake H, Nakayama H, Tanaka S, Tomizawa D, Shiba N, Saito AM, Tawa A, Shimada A, Iwamoto S, Hayashi Y, Koike T, Horibe K, Manabe A, Mizutani S, Taga T, Adachi S. Miyamura T, et al. Among authors: tanaka s. Br J Haematol. 2019 Apr;185(2):284-288. doi: 10.1111/bjh.15799. Epub 2019 Feb 19. Br J Haematol. 2019. PMID: 30784060 Free article.
Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Aoki T, Takahashi H, Tanaka S, Shiba N, Hasegawa D, Iwamoto S, Terui K, Moritake H, Nakayama H, Shimada A, Koh K, Goto H, Kosaka Y, Saito AM, Horibe K, Kinoshita A, Tawa A, Taga T, Adachi S, Tomizawa D. Aoki T, et al. Among authors: tanaka s. Br J Haematol. 2021 Apr;193(1):176-180. doi: 10.1111/bjh.16656. Epub 2020 Apr 26. Br J Haematol. 2021. PMID: 32337716 Free article.
13,834 results
You have reached the last available page of results. Please see the User Guide for more information.